What does a CAP mock inspection actually cover?

A Bench Standard mock inspection simulates a real CAP survey day. We use the current edition of the All Common, Laboratory General, and discipline-specific checklists; score every applicable item; observe staff in real workflow; and deliver a written findings report categorized as Critical, Major, or Minor with corrective-action deadlines mapped to specific checklist items. The methodology is anchored to CAP's Laboratory Accreditation Program inspection process and 42 CFR §493.1230 series quality system requirements.

How long does a CAP rapid readiness engagement take?

Two to four weeks for a Mock Inspection engagement (typical), four to six weeks for a Competency Assessment Program build, and four to eight weeks for a QC Program Design engagement. Each timeline is published, fixed, and stated on the service page before you sign.

What are the six elements of CLIA competency assessment?

Per 42 CFR §493.1451(b)(8): direct observation of routine patient testing; monitoring the recording and reporting of test results (including intermediate results, QC records, proficiency testing records, and preventive maintenance records); direct observation of instrument maintenance and function checks; assessment via previously analyzed specimens, internal blind samples, or external proficiency testing samples; problem-solving skill assessment; and evaluation of analytical interpretation skill. All six are required — not optional, not selectable.

Who can perform competency assessments under CLIA?

For high-complexity testing personnel, the technical supervisor (TS) is the assessor of record, with delegation rules defined under 42 CFR §493.1451. For moderate-complexity testing, the technical consultant (TC) is the analog assessor under 42 CFR §493.1413(b)(8). Delegation must be documented; the TS retains responsibility regardless of who performs the observation.

When did CMS stop sending paper CLIA certificates?

Effective March 1, 2026. After that date CMS does not issue paper certificates or mail fee coupons. All CLIA fees flow through Pay.gov; certificates and inspection notices arrive via the email address of record. Labs must (1) register a monitored email, (2) add CMS to the safe-senders list, and (3) ensure CMS-116 elects electronic communication.

CMS-3326-F is the CLIA final rule published December 28, 2023 (Fed. Reg. doc. 2023-28170) that updated personnel qualifications under 42 CFR Part 493 Subpart M, effective December 28, 2024. It changed the educational and experience requirements for laboratory director, technical consultant, technical supervisor, clinical consultant, general supervisor, and testing personnel. (Note: CMS-3355-F is a separate, earlier rule covering CLIA proficiency testing analytes, not personnel.)

What are the required elements of a CAP-compliant SOP?

The minimum element set under CLSI QMS01-Ed5 (formerly GP26) is: title, purpose, scope, principle, specimen requirements, reagents and materials, quality control, calibration, procedural steps, results reporting, expected values, calculations, limitations, safety, references, and a document-control footer. CAP All Common GEN.20377 enforces biennial review with director signature.

How often do laboratory SOPs need to be reviewed?

At minimum biennially under CAP All Common GEN.20377, with director or designee signature dating each review. Whenever a method changes, an instrument changes, a reagent lot changes in a way that affects the SOP, or a regulatory advisory affects the procedure, the SOP must be revised — not just re-signed.

What are Westgard rules and which ones should our lab use?

Westgard rules are multi-rule statistical control procedures (1-3s, 2-2s, R-4s, 4-1s, 10x, etc.) that combine to balance error detection against false rejection. The right combination depends on the analyte's sigma metric — high-sigma methods need fewer rules; low-sigma methods need tighter rules. The program selects rules per analyte from the lab's actual performance data.

The Individualized Quality Control Plan is a CMS-recognized QC pathway under 42 CFR §493.1256 that allows the lab, after a documented risk assessment, to use the manufacturer's recommended QC frequency rather than the default external QC frequency.

What is the difference between RUO and clinical testing under CLIA?

Research-use-only (RUO) testing is performed for research purposes only and is not used to make patient management decisions. Clinical testing under CLIA generates results used for diagnosis, treatment, or management of a patient. The CLIA program applies to clinical testing — every clinical specimen run for billing or clinical use requires the lab to hold an appropriate CLIA certificate.

What is an LDT and how is it validated?

A Laboratory Developed Test is a test designed, manufactured, and used within a single CLIA-certified high-complexity laboratory. Under CLIA, LDTs require analytical validation covering accuracy, precision, sensitivity, specificity, reportable range, and reference intervals; high-complexity LDTs also require clinical performance characteristics.

Is hourly billing available?

No. Every engagement is fixed-fee against a written scope. Hourly billing misaligns incentives. Invoicing is 50% at engagement start and 50% at delivery, net 15.

What is the difference between this and hiring a compliance officer?

A dedicated compliance FTE costs $90,000–$140,000 fully loaded in the DMV market. The Monthly Compliance Retainer at $1,500–$3,000/month covers regulatory monitoring, SOP review cycle, and competency-program oversight — at $18,000–$36,000 annually. The retainer does not provide on-site daily presence; for labs that need expertise but not daily presence, the retainer replaces the FTE.

Why does the consultant being active on the bench matter?

Compliance is downstream of operations. A consultant who has not run a bench in five years writes recommendations that look right on paper but break the actual workflow. Active bench experience keeps the recommendations operational — they survive contact with a Saturday short-staffed shift.

Do you work with biotech startups in Maryland's I-270 corridor?

Yes. Startup Lab Consulting ($5,000–$10,000) covers the regulatory pathway from research-use-only to CLIA-certified clinical testing, including certificate type selection, personnel qualifications under 42 CFR Part 493 Subpart M, and Maryland-specific permit guidance under COMAR 10.10.03 (Medical Laboratories—Licenses).

Maryland COMAR 10.10 Changes: What Clinical Laboratories Need to Know

Ugochi Ndubuisi
Apr 18
2 min read

Effective March 1, 2026, Maryland updated COMAR 10.10.01 through 10.10.08 and 10.10.12 — the state regulations governing clinical laboratories. If your lab operates in Maryland, these changes affect how you handle waived testing, quality control, and state-level compliance documentation.

The Biggest Change: CLIA-Waived Tests Are Now Automatically 'Excepted'

Under the updated COMAR 10.10, tests that CMS classifies as CLIA-waived are now automatically categorized as 'excepted' at the state level. This eliminates what had been a confusing dual-classification system where labs sometimes needed separate state approval for tests that were already federally waived.

For most labs, this simplification is welcome. But it also means your QC requirements for waived tests now default to manufacturer IFU (instructions for use) only — no additional state-mandated QC beyond what the manufacturer specifies.

QC for Waived Tests: Follow the Manufacturer

The updated regulations clarify that quality control for waived tests must follow the manufacturer's instructions for use — no more, no less. This aligns Maryland with the federal CLIA framework under 42 CFR Part 493 and eliminates any ambiguity about whether state rules required additional QC beyond what the manufacturer specified.

What this means in practice: if your rapid strep test manufacturer says to run a positive and negative control once per new kit lot and once per new shipment, that is your QC requirement. You do not need to run daily controls unless the manufacturer specifies it.

What Didn't Change

Maryland's regulations for moderate and high-complexity testing remain largely unchanged. Personnel qualifications, proficiency testing requirements, and quality assessment standards under COMAR 10.10 continue to mirror the federal CLIA framework. If your lab only performs moderate or high-complexity testing, the March 2026 updates have minimal operational impact.

Action Items for Maryland Labs

Review your waived test menu and confirm that your QC practices match the manufacturer's IFU — not an outdated internal policy that may have been more conservative than required.
Update any SOPs that reference the old COMAR 10.10 classifications or impose state-specific QC requirements beyond the manufacturer's IFU for waived tests.
Verify your Maryland OHCQ documentation reflects the current 'excepted' designation for all CLIA-waived tests you perform.
Brief your point-of-care testing coordinators on the change — they manage the bulk of waived testing in most health systems.

The Bigger Picture

This COMAR update is part of a broader trend: states aligning their laboratory regulations with the federal CLIA framework rather than maintaining separate, sometimes conflicting requirements. For multi-state laboratory networks and reference labs serving the DMV region, this simplification reduces the compliance burden.

But simplification does not mean you can ignore it. If your SOPs and QC documentation still reference the old COMAR language, you have a documentation gap — and documentation gaps are exactly what surveyors look for.

Need Help Updating Your SOPs?

Bench Standard Consulting offers SOP gap analysis and remediation services starting at $1,500. We audit your existing procedures against the current COMAR 10.10, CAP checklists, and 42 CFR Part 493 — then rewrite what needs fixing. Every SOP is mapped to specific regulatory citations so your documentation is survey-ready.

Book a free 30-minute discovery call to discuss your lab's compliance posture.